objectives educate physicians and nurses on practical management tips for diabetes control. identify...
TRANSCRIPT
![Page 1: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/1.jpg)
![Page 2: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/2.jpg)
Objectives
• Educate physicians and nurses on practical management tips for diabetes control.
• Identify goals for diabetes therapy in patients with CKD with emphasis on prevention and medication side effects
![Page 3: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/3.jpg)
At the end of this online presentation you should• Understand the relationship between
diabetes and kidney disease• Know the difference between type 1
and Type 2 diabetes• Be familiar with some of the clinical
trials that have shaped our progress• List key management objectives for
Diabetes as it relates to progressive CKD
• Be familiar with therapy for diabetes
![Page 4: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/4.jpg)
Incidence ESRD due to Diabetes in Network 14 is 206/million
Each year in Texas 206/million patients start dialysis because of diabetic nephropathy.Texas has the highest incidence in the nation. Source: USRDS
![Page 5: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/5.jpg)
Diabetes is the main cause of ESRD
![Page 6: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/6.jpg)
Predicted and actual cost adjusted by diagnosis
Dialysis management of diabetic ESRD patients, particularly with heart failure
Source: USRDS
![Page 7: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/7.jpg)
• Type 1 – onset in youth, destruction of beta cells and a requirement for insulin
• Type 2 – onset as adult or young adult, related to insulin resistance. May be treated with lifestyle modification, oral medications, and later may require insulin
![Page 8: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/8.jpg)
Type 1 Diabetes– Insulin-dependent/Juvenile onset– 20 to 30% develop microalbuminuria after 15 years
• Amin, R, Widmer, B, Dalton, N & Dunger, DB: Unchanged incidence of Microalbuminuria in Children with Type 1 Diabetes since 1986: A UK based inception cohort. Arch Dis Child:adc.2008.144337, 2009.
– Of the ones who develop this less than half progress to diabetic nephropathy
– Associated with microvascular disease – retina and kidney. The increased sugar is neurotoxic – hence neuropathy
– 2.2 percent will develop ESRD in 20 years and 7.8 percent in 30 years
• Finne P, Reunanen A, Stenman S, et al. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005; 294: 1782-1787.
![Page 9: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/9.jpg)
Type 1 Diabetes (Continued)– The microalbuminuria can regress – and it is not
always related to the use of ACE or ARB therapy• Perkins, BA, Ficociello, LH, Silva, KH, Finkelstein, DM,
Warram, JH & Krolewski, AS: Regression of Microalbuminuria in Type 1 Diabetes. N Engl J Med, 348:2285-2293, 2003
– The risk of developing kidney failure after 20 to 25 years in patients who have no proteinuria is low
– Labile swings in blood sugar because of autonomic insufficiency
– Always requires insulin– If diabetic nephropathy develops, the patient will
develop insulin resistance – metabolic syndrome due to kidney disease. Atherosclerosis and hypertension are not primary but secondary events
![Page 10: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/10.jpg)
Type 2 Diabetes• Common in Hispanics, Native Americans and Pima Indians• Incidence of ESRD is lower, but the disease is more frequent – thus
it is the most common cause of renal failure• United Kingdom Prospective Diabetes Study
– UKPDS – large British study, (predominantly Caucasians)– Adler, AI, Stevens, RJ, Manley, SE, Bilous, RW, Cull, CA &
Holman, RR: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int, 63:225-32, 2003.
– Incidence of microalbuminuria 25% but incidence of ESRD only 0.8%
– Microlbuminuria patients spent an average of 11 years before progressing to overt proteinuria
– Only 2.3% progress from macroalbuminuria to ESRD
![Page 11: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/11.jpg)
Type 2 Diabetes (Continued)• Disease progresses slowly over many years
and is associated with proteinuria. The urine should show more than just red cells.
• In the elderly, it is impossible to clinically distinguish the hypertensive and atherosclerotic effects from the diabetic effects without a kidney biopsy.
• Not associated with labile blood sugar swings• Insulin resistance
![Page 12: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/12.jpg)
Incidence of Type 2 Diabetes• Doubled in past 20 years• Framingham Offspring Study• Related to Lifestyle Change and Obesity• BMI Increase confirmed by NHANES Dataset
– Source: American Heart Association• Prevalence of Diagnosed and Undiagnosed
Diabetes in the United States, All Ages, 2007– Total: 23.6 million people
• 7.8 percent of the population—have diabetes.• Diagnosed: 17.9 million people• Undiagnosed: 5.7 million people
– Source: NIDDK
![Page 13: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/13.jpg)
Metabolic Syndrome
• Characterized by insulin resistance – 50 to 75 million Americans– High blood pressure– High blood sugars– High levels of triglycerides– Low levels of HDL– Increased waist line
• It is associated with– Diabetes, Hypertension, stroke, cardiovascular disease
• Dominant Features– Obesity, lack of exercise
![Page 14: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/14.jpg)
Diet Plays a Major Role
• The Sugar Fix – High fructose corn syrup
• Decreases the ATP in cells – this decreases cell respiration and causes hypoxia in cells
• Releases cytokines that impair nitrous oxide synthesis
• Releases uric acid which increases blood pressure• Causes leptin resistance (Leptin turns off the
appetite) continue to be hungry• Supersized – HFCS is in many soft drinks and other
products• Americans eat more sugar, now have an epidemic
of obesity, the metabolic syndrome, heart disease and diabetes
![Page 15: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/15.jpg)
Management Objectives
• Lifestyle– An aspirin a day– Smoking and Exercise– Weight/cholesterol
• Blood Pressure• ACE and ARB• Vitamin D• Diabetes Control
![Page 16: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/16.jpg)
Lifestyle - An aspirin a day - Smoking and Exercise - Weight/cholesterol
• Can be a rewarding way to keep diabetes under control.
• Requires a lifelong strategy• Diet: Avoid fructose, excess salt,
trans fats and excess carbohydrates• Two alcoholic beverages at most/day• 25% incident diabetics are smokers
– Potentiates kidney disease– Increases inflammation
• Gentle aerobic exercise• Aspirin a day to reduce
cardiovascular risk
![Page 17: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/17.jpg)
ACE and ARB
![Page 18: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/18.jpg)
Blood pressure goal in CKD
< 130/80 • Any person with abnormal kidneys
is at risk for heart disease• Most patients will require two or
more medications to control their blood pressure
• Lowering the systolic blood pressure to <130 mm Hg is usually associated with a reduction in diastolic blood pressure to <80 mm Hg
Adapted from American Journal of Kidney Diseases, Vol 43, No 5, Suppl Suppl 1 (May), 2004: pp S14-S15
![Page 19: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/19.jpg)
Many blood pressures medications may be needed to control severe blood pressure
![Page 20: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/20.jpg)
Blood pressure is poorly controlled in patients with kidney disease
![Page 21: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/21.jpg)
![Page 22: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/22.jpg)
![Page 23: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/23.jpg)
![Page 24: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/24.jpg)
ACES & ARBS are the two major
classes of medicationsused to treat
high blood pressure
ACES & ARBS are the two major
classes of medicationsused to treat
high blood pressure
![Page 25: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/25.jpg)
Effect of ACE Inhibitorson Progression of CKD
Maschio. N Engl J Med. 1996;334:939.
![Page 26: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/26.jpg)
Proteinuria is a powerful determinant of Proteinuria is a powerful determinant of renal deterioration.renal deterioration.
Source: The New England Journal of Medicine -- November 12, 1998 -- Vol. 339, No. 20 Mechanisms of Disease: Pathophysiology of Progressive Nephropathies Giuseppe Remuzzi, Tullio Bertani
![Page 27: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/27.jpg)
Collaborative Study Group – Reduction of proteinuria in Type 1 DM with ACE
20%
-40%
37%
22%
7% 4%
-60
-40
-20
0
20
40
60
Changes in proteinuria
Incidence of ESRD
Incidence of mortality
Per
cen
t
PlaceboCaptopril
Lewis EJ, et al. N Engl J Med. 1993;329:1456-1462.
![Page 28: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/28.jpg)
ARBS in Diabetes – The RENAAL Trial
– (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)
• Brenner. BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G,Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study InvestigatorsEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861-9.
– Randomized, double-blind, multicenter, placebo-controlled– Losartan Vs Placebo and conventional BP medications– 1513 patients– Outcome: Composite of doubling creatinine, ESRD, Death– Followup 3.4 years – RESULT: Reduced doubling of creatinine by 25% and ESRD
by 28%
![Page 29: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/29.jpg)
ARBS in Diabetes - IRMA• IRMA (Irbesartan Microalbuminuria) study
– Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P;Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):870-8
• multicenter, randomized, double-blind, placebo-controlled trial, randomized
• 590 patients with type 2 diabetic nephropathy (albuminuria)• Randomized to irbesartan, 150 mg, 300 mg (Avapro) or placebo• Blood pressure medications allowed • Endpoint was overt nephropathy – a urine albumin at least 30%
greater than baseline– 10/194 (300 mg group) – reached endpoint– 19/195 (150 mg group) – reached endpoint– 30/201 (Placebo group) – reached endpoint– Blood pressure unchanged
![Page 30: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/30.jpg)
ARBS in Diabetes IDNT• IDNT (Irbesartan Diabetic Nephropathy Trial)
– Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
• Randomized, double-blind, placebo-controlled• 1715 patients to irbesartan,amlodipine or placebo• 2.6 years• BP therapy allowed (with exception on study drugs)• Result:
– Lowered risk of developing ESRD by 23%
![Page 31: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/31.jpg)
What slows progression?
• Proven interventions– Control blood sugar in diabetics– Strict blood pressure control– Certain meds: ACES (Angiotensin-converting enzyme
inhibition) and ARBS (angiotensin-2-receptor blockade)
• Studied, but inconclusive– Dietary protein restriction– Lipid lowering therapy– Partial correction of anemia– Vitamin D administration
![Page 32: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/32.jpg)
How are we doing?
• Elderly diabetic patients• Medical insurance claims• 65 years and older• 30,750 patients studied (58.7% also
had high blood pressure and/or protein in the urine)
• Of these only 50.7% (CI 50.0-51.4) received an ACE or ARB
Am J Kidney Dis. 2005 Dec;46(6):1080-7.
![Page 33: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/33.jpg)
ACCOMPLISH TRIAL• Avoiding Cardiovascular Events Through Combination Therapy in Patients Living
With Systolic Hypertension (ACCOMPLISH) trial• Has been stopped early – accomplished its goal• benazepril plus amlodipine better than benazepril plus hydrochlorothiazide• Study group – Hypertensives at risk secondary to previous events or diabetes• 11,464 patients
– ≥ 55 years old– BP ≥ 160 – 60.4% with diabetes– Obese– Cardiovascular, renal disease or target damage
• 70% treated with two or more agents• Only 37.5% had blood pressure les than 140/90• Endpoints – cardiovascular morbidity MI, (stroke, unstable angina, bypass) or
death• ACE/amlodipine Risk reduced by 20% compared with ACE/diuretic
– SOURCE: Presented by KA Jamerson, American College of Cardiology, March 31, 2008
![Page 34: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/34.jpg)
![Page 35: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/35.jpg)
Vitamin D
• Type 1 Diabetes in children might be prevented with vitamin D supplements and 5 – 10 minutes of noon sunlight
• Epidemiology study• UCSD
– SOURCE: University of California - San Diego. "Sun Exposure And Vitamin D Levels May Play Strong Role In Risk Of Type 1 Diabetes In Children." ScienceDaily 5 June 2008. 10 March 2009 <http://www.sciencedaily.com /releases/2008/06/080605073804.htm>.
![Page 36: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/36.jpg)
![Page 37: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/37.jpg)
Sulfonylureas
Biguanides
Thiazolidinediones “Glitazones”
Meglitinides
DPP-4 Inhibitors
Incretin Memetics
Insulin
![Page 38: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/38.jpg)
ADA Guidelines
![Page 39: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/39.jpg)
TYPE NAME MECHANISM ROUTE, TIME
Sulfonylureas GlimepirideGlipizideGlyburide
Increases insulin production through K channels of beta cells
Po qd or bid
Biguanides Metformin (Glucophage)
Reduce hepatic glucose output and increase its muscle uptake
Po bid – tidXR – po qd
Thiazolidinediones “Glitazones”
Rosiglitazone (Avandia)Pioglitazone (Actos)
PPAR gamma ligand – improves glucose utilization
Po qd
Meglitinides Repaglinide (Prandin)Nateglinide (Starlix)
Close K channel and open Ca channel in Beta cell – increasing insulin
Po 5 – 30 min AC
DPP-4 Inhibitors
Sitagliptin (Januvia) Blocks, DPP-4 which catalyzes enzyme breaking down insulin
100 mg po qd
Incretin Memetics
Exenatide (Byetta) Stimulates beta cells and slows digestion
10 mcg sc 60 min AC AM and PM meal
![Page 40: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/40.jpg)
SULFONYUREAS
• First category of oral agents for diabetes – now in third generation
• Mainly for type 2 diabetes – work on existing beta cells
• Increase secretion of insulin by binding to potassium channels and opening calcium channels
• Can cause hypoglycemia and weight gain
![Page 41: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/41.jpg)
BIGUANIDES
• Metformin used in obese type 2 diabetics• Maximum reduction in HgbA1c after 6
months• Action lasts additional 9 months with
thiazolidinedione• With sulfonureas HgbA1C tends to increase• Reduced cardiovascular risks
– Pharmacotherapy. 2007 Aug;27(8):1102-10.Loss of glycemic control in patients with type 2 diabetes mellitus who werereceiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy.Riedel AA, Heien H, Wogen J, Plauschinat CA.
![Page 42: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/42.jpg)
ROSIGLITAZONE • Controversy regarding risk of
causing MI– Odds ratio 1.43
• ADOPT – increased fractures• Associated with macular edema• Stimulates the PPARγ receptor• Not to be used in heart failure
– Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med. 2007;356(24):2457-2471.
![Page 43: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/43.jpg)
INCRETIN MIMETICS• Exenatide (Byetta)• From the saliva of the gila monster• Incretin – mimetic
– Enhances beta cell insulin– Blocks glucagon– Delays gastric emptying
• Injection sub cutaneously 30 to 60 minutes before first and last meal – adjunctive therapy
• Side effects – Gastrointestinal symptoms• FDA warning – pancreatitis – may be fatal
![Page 44: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/44.jpg)
WHEN TO START INSULIN• Start with oral agents (metformin) and
proceed to insulin if goal is not achieved• May be able to manage for up to 6 years• HgbA1C – use a target• In kidney patients and those who may be
operating heavy machinery – because of the risk of hypoglycemia – may want to have a higher goal
• Mono-duo-triple therapy – disease has advanced
![Page 45: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/45.jpg)
HgbA1C
• American Diabetic Association 7.0%• American Society of Clinical
Endocrinologist 6.5%• Many local endocrinologist 6.0%• CONTROVERSY: The lower the HgbA1C
the lower the risk of microvascular disease, but the higher the risk of hypoglycemia
![Page 46: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/46.jpg)
![Page 47: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/47.jpg)
PREPARATION ONSET PEAK DURATION
MAX DURATION
RAPIDACTING
Lispro (Humalog) 5 – 15 min
.5-1.5 hr 5 hr 4-6 hr
Aspart (Novolog)
Glulisine (Apidra)
SHORT Regular .5 – 1 hr 2 – 3 hr 5 – 8 hr 6 – 10 hr
INTERMEDIATE NPH (isophane) 2 – 4 hr 4-10 hr 10-16 hr 14-18 hr
Lente (zinc) 2 – 4 hr 4-12 hr 12-18 hr 16-20 hr
LONG Ultralente 6 – 10 hr 10-16 hr 18-24 hr 20-14 hr
LONG ANALOGUE
Glargine (Lantus) 2 – 4 hr No Peak 20-24 hr 24 hr
COMBINATIONS 70/30 NPH/Reg .5 to 1 hr Dual 10 -16 hr 14-18 hr
50/50 NPH/Reg
CONBINATIONANALOGUES
75/25 NPL/lispro 5 – 15 min
Dual 10 -16 hr 14-18 hr
70/30 NPL/aspart
Adapted from Hirsch IB, Edelman SV Practical Management of Type 1 Diabetes, PCI Book,, West Islip Ny (2005)
![Page 48: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/48.jpg)
INSULININSULIN• Glucose homeostasis declines –
– Loss of post prandial glycemic control
– Decline in control around breakfast– Nocturnal Hyperglycemia
• Consider prandial insulin before starting basal insulin
• Basal insulin typically started in type 2
![Page 49: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/49.jpg)
Diabetes and the eye• Type 1
– Almost always have retinopathy and neuropathy by the time they develop nephropathy, but many patients with retinopathy do not have nephropathy
– Detected clinically by the doctor or opthalmologist
• Type 2– Retinopathy will likely be accompanied by
nephropathy– If no retinopathy is present, they may have
something other than diabetic nephropathy
![Page 50: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/50.jpg)
Background Diabetic Retinopathy
NORMALBDR
![Page 51: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/51.jpg)
ADOPT A Diabetes Outcome Progression Trial• 4360 Patients with type 2 diabetes• Rosiglitazone, metformin, glyburide• Double blind randomized• Treated 4 years• Outcome – time to medial failure• Results
– Monotherapy at five years – when compared with metformin
– 32% risk reduction with rosiglitazone– 63% risk reduction with glyburide– Better blood sugar control with glitazone
• N Engl J Med. 2006 Dec 7;355(23):2427-43. Epub 2006 Dec 4..Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, LachinJM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group.
![Page 52: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/52.jpg)
DREAM• Lancet. 2006 Sep 23;368(9541):1096-105. • Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance
or impaired fasting glucose: a randomised controlled trial.• DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial
Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR.
• Multicenter – RCT – Rosiglitazone v placebo – follow up median of 3 years• Primary Outcome – Composite – incident diabetes or death• Type Intent to treat• GOAL: prevent type 2 diabetes in high risk patients• 5269 adults ≥ 30 years old with abnormal glucose tolerance, no prior CV diease• Composite reached
– Rosiglitazone 11.6%– Placebo 26%
• Euglycemic – Rosiglitazone 50.5%– Placebo 30.3%– Cardiovascular
• Heart Failure– Rosiglitazone 0.5%– Placebo 0.1%
![Page 53: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/53.jpg)
Common Medications to avoid in CKD• NSIADS
– Ibuprofen (Motrin)– Indomethacin (Indocin)– Naproxen (Aleve, Anaprox, Naprosyn)– (Celecoxib) Celebrex– (Rofecoxib) Vioxx
• METFORMIN– Glucophage, Diaformin
![Page 54: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/54.jpg)
DRUGS THAT RAISE POTASSIUM
• Beta blockers like propanolol• ACES• ARBS• Renin inhibitors• NSAIDS• Potassium sparing diuretics
![Page 55: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/55.jpg)
Lowering Potasium
• Glucose and insulin• Albuterol• Kayexalate• Loop diuretics• Thiazide diuretics
![Page 56: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/56.jpg)
Hardening of the Arteries
• Vascular Calcification– Potentiated by metabolic syndrome and
kidney disease– Accumulation of phosphorus with decreased
bone turnover in CKD associated with the metabolic syndrome potentiates changes in cells inside blood vessel walls
– These vessels accumulate phosphorus and calcium – leading to vascular calcification
– Common in diabetes and in CKD
![Page 57: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/57.jpg)
Diabetes Complications• Vascular Disease
– Peripheral vascular disease– Amputations
• Autonomic insufficiency– Gastroparesis– Postural hypotension– Bladder dysfunction
• Neuropathy– Charcot Joints– Burning Neuropathy
![Page 58: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/58.jpg)
Impact of diabetes on dialysis blood pressure management• Autonomic insufficiency
– BP drops and very labile
• Medial Calcification– Wide Pulse Pressure
• Hypertensive cardiomyopathy– Preload– Cardiac function– Afterload
![Page 59: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/59.jpg)
Summary of prevention
• Lifestyle Modification• ACE inhibitor therapy• ARB therapy• Control Blood sugar• Control Blood pressure• Vitamin D• Titrate proteinuria
![Page 60: Objectives Educate physicians and nurses on practical management tips for diabetes control. Identify goals for diabetes therapy in patients with CKD with](https://reader035.vdocuments.mx/reader035/viewer/2022070306/5516309d550346a2308b5fd6/html5/thumbnails/60.jpg)